Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
The commercial real estate sector closed out 2025 with renewed stability, as the Real Estate Roundtable’s latest sentiment index shows rising confidence and improving market fundamentals. Executives report better access to capital, stronger performance in residential, retail, and hospitality, and early signs of recovery in the office market. With financing loosening and asset values climbing, the outlook for 2026 is increasingly optimistic, creating fresh opportunities for both seasoned professionals and newcomers preparing to enter the field.
The CFPB is proposing changes to how lenders evaluate “disparate impact” under the Equal Credit Opportunity Act, potentially tightening the scrutiny on credit decisions that unintentionally disadvantage protected groups. These updates could reshape underwriting models, lending criteria, and compliance requirements — ultimately influencing mortgage approvals, buyer qualifications, and day‑to‑day real estate activity.
Florida’s insurance crisis has become the defining issue heading into 2026, with Republicans touting recent market improvements while Democrats argue families are still being crushed by soaring premiums. From billion‑dollar auto insurance refunds to condo markets destabilized by post‑Surfside rate spikes, the state’s political divide is shaping the future of real estate, insurance, and affordability for millions.
October 2025 brought a wave of major regulatory updates across insurance, finance, and compliance. From stricter oversight on retail insurers and new FCA rules on ESG and travel insurance, to EIOPA’s EU‑wide consultations and refreshed corporate governance standards, regulators signaled higher expectations and faster change ahead. For professionals—and those pursuing licenses—these shifts directly impact risk management, product design, and consumer outcomes, making regulatory awareness a critical competitive advantage.
After nearly two years of sluggish activity, commercial real estate lending is finally accelerating—fast. New data from CBRE shows loan closings jumped 112% year‑over‑year in Q3 2025, reaching their highest level since 2018. With interest rates stabilizing and credit spreads tightening, investors are returning, banks are re‑entering the market, and multifamily financing is dominating once again. The long‑stalled deal flow is thawing, signaling renewed momentum heading into 2026.
Farmers Insurance is lifting its cap on new homeowner policies in California after two years of limiting growth, signaling a shift in the state’s strained insurance market. The expansion comes with a proposed 6.99 percent rate increase that still needs regulatory approval. Supporters call it a turning point driven by new wildfire‑risk rules, while consumer advocates warn the reforms contain loopholes and could lead to higher costs for homeowners.
